Close Menu

NEW YORK – Liquid biopsy firm Biocept has completed a 1-for-10 reverse stock split to regain compliance with the Nasdaq $1.00 minimum bid price requirement. As a result of the split, effective with the open of the market on Tuesday, the firm's common stock is now trading on a split-adjusted basis.

Authorization for the reverse split was approved by the company's stockholders at Biocept's 2020 annual shareholder meeting, although the vote was delayed several times due to an insufficient number of ballots in favor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.